Senseonics shares jumped as much as 30% during trading on Tuesday 10 November 2026, touching $12.80, after the diabetes technology company more than doubled third-quarter revenue and raised its full-year guidance for the third time. The shares later gave back much of the gain, closing at $10.03, up 2.3% on the day.

Revenue rose to $19.6 million in the quarter, up about 140% from $8.1 million a year earlier, according to MarketBeat. US revenue climbed to $16.8 million from $6.4 million, and gross margin improved to about 62% from 43%. The company lifted its 2026 revenue guidance to $68 million to $70 million, up from $62 million to $66 million and above the $64.2 million consensus estimate, and raised its full-year gross margin outlook to more than 60%.

Loss widens despite the sales jump

The quarter was not all good news. The net loss widened to $32.7 million, or $0.50 per share, from $19.5 million a year earlier, slightly worse than the $0.49 loss analysts had expected. Management said it expects Senseonics to become a $100 million revenue company in 2027, with formal guidance to follow early next year, as reported by Kalkine.

Analysts responded to the update. Barclays raised its price target on the stock to $11 from $10, while HC Wainwright reaffirmed its Buy rating and set a $14 price target.

Senseonics makes Eversense, an implantable continuous glucose monitoring system, and it is the only maker using optical fluorescence detection to track glucose. The company still loses money and may need further financing, so the one-day jump is no guarantee of lasting gains.